Bibliography

1. Altomare I, Irwin BB, Zafar Y, Houck K, Maloney B, Greenup RA, & Peppercorn JM. Physician experience and attitudes toward addressing the cost of cancer care.‏ J Clin Oncol 2014; 32(15):6561-6561.
2. Becker G, Murphy K, Philipson T. The Value of Life Near Its End and Terminal Care. NBER Working Paper No. 13333. Cambridge, MA: National Bureau of Economic Research, 2007:1–21.
3. Ben-Aharon O, Magnezi R, Leshno M, & Goldstein DA. Association of immunotherapy with durable survival as defined by value frameworks for cancer care. JAMA Oncol 2018; 4(3):326-332.‏
4. Berry, S. R., Bell, C. M., Ubel, P. A., Evans, W. K., Nadler, E., Strevel, E. L., & Neumann, P. J. (2010). Continental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. *Journal of Clinical Oncology*, *28*(27), 4149-4153.‏
5. Brock DW. Ethical issues in the use of cost effectiveness analysis for the prioritization of health care resources. In: Anand S, Peter F, Sen A, eds. Public Health, Ethics, and Equity. Oxford: Oxford University Press, 2004: 201–223.
6. Bunnik, E. M., & Aarts, N. (2021). The Role of Physicians in Expanded Access to Investigational Drugs: A Mixed-Methods Study of Physicians’ Views and Experiences in The Netherlands. *Journal of Bioethical Inquiry*, 1-16.‏
7. Charles, C., Whelan, T., & Gafni, A. (1999). What do we mean by partnership in making decisions about treatment?. *Bmj*, *319*(7212), 780-782.‏
8. Charmaz, K. (2002). Qualitative Interviewing and Grounded Theory Analysis, in Jober F. Gubrium and James A. Holstein (eds.) *Handbook of Interview Research: Context and Methods*, Thousand Oaks: Sage.
9. Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. et al. A standardized, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26(8):1547-1573.‏
10. Davis C. Drugs, cancer and end-of-life care: a case study of pharmaceuticalization? Soc Sci Med 2014; <http://www.sciencedirect.com/> science/article/pii/S0277953614007965
11. Dopelt K, Urkin J, Bachner Y, Yahav Z, Davidovitch N. The virtues of the "Good Doctor": Doctors' versus public perception. Social Issues in Israel, 2020; 29(2), 323-342; doi: https://doi.org/10.26351/SIII/29-2/3.
12. Emanuel EJ, Fuchs VR. The perfect storm of overutilization. *JAMA* 2008; 299:2789–91.
13. Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley Lecture. JAMA Otolaryngol Head Neck Surg 2014; 140: 1225–1236.
14. Gattellari M, Butow PN, & Tattersall MH. Sharing decisions in cancer care. Social science & medicine 2001; 52(12), 1865-1878.‏
15. ‏ Henrikson NB, Tuzzio L, Loggers ET, Miyoshi J, & Buist DS. Patient and oncologist discussions about cancer care costs. Supportive Care in Cancer 2014; *22*(4): 961-967.‏
16. Jagsi R: Debating the oncologist’s role in defining the value of cancer care: We have a duty to society. J Clin Oncol 2014; 32:4035-4038.
17. Porter ME. What is value in health care? N Engl J Med 2010; 363: 2477–2481.
18. Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010; 21: 7–12.
19. Saletti P, Sanna P, Gabutti L, & Ghielmini M. Choosing wisely in oncology: necessity and obstacles. ESMO open 2018;*3*(5): e000382.‏
20. Sprecher, S., Fehr, B., & Zimmerman, C. (2007). Expectation for mood enhancement as a result of helping: The effects of gender and compassionate love. *Sex roles*, *56*(7), 543-549.‏
21. Sulmasy D, Moy B: Debating the oncologist’s role in defining the value of cancer care: Our duty is to our patients. J Clin Oncol 2014; 32:4039-4041.
22. Thiese MS, Ronna B, Ott U. P value interpretations and considerations. J Thorac Dis 2016; 8(9): E928-E931. doi:10.21037/jtd.2016.08.16

Fojo & Mailankody, 2014 √

Davis, 2014 √

Porter, 2010 √

Cherny et al., 2010 2015? √

Ben-Aharon et al., 2018 √

Emanuel & Fuchs, 2008 √

Saletti et al., 2018 √

Becker et al., 2007 √

Brock, 2010 2004? √

Altomare et al., 2014 √

Jagsi, 2014 √

Sulmasy & Moy, 2014 √

Thiese, Ronna & Ott (2016) √

Charmaz, 2002 √

Berry et al., 2010 √

Charles et al., 1999 √

Dopelt et al., 2020 √

Bunnik & Aarts, 2021√